Suppr超能文献

头孢妥仑匹酯在儿科领域的药代动力学和临床研究。ME1207儿科研究组

[Pharmacokinetic and clinical studies of cefditoren pivoxil in the pediatric field. Pediatric Study Group of ME1207].

作者信息

Fujii R, Yoshioka H, Okuno A, Fujita K, Murono K, Maruyama S, Sakata H, Iseki K, Wagatsuma Y, Fukushima N

机构信息

Department of Pediatrics, School of Medicine, Teikyo University.

出版信息

Jpn J Antibiot. 1993 Jan;46(1):95-114.

PMID:8455336
Abstract

Cefditoren pivoxil (ME1207) in granules, a new oral cephalosporin, was pharmacokinetically and clinically evaluated in the pediatric field and the following results were obtained: 1. Pharmacokinetics In infants administered single oral doses of 3 mg (potency)/kg and 6 mg/kg, the Cmax was 1.54 +/- 0.68 and 2.85 +/- 1.03 micrograms/ml; Tmax, 2.27 +/- 1.08 and 2.06 +/- 1.16 hours; T 1/2, 2.22 +/- 1.95 and 1.68 +/- 0.66 hours; and AUC (0-infinity), 7.43 +/- 3.68 and 11.90 +/- 4.51 micrograms.hr/ml, respectively. These values have indicated that the drug has a dose-dependent pharmacokinetic behavior. Urinary concentrations peaked in 2-4 hours after administration. Urinary recovery rates in the first 8 hours were 19.4 +/- 6.6% at 3 mg/kg and 17.1 +/- 5.2% at 6 mg/kg. 2. Clinical results The clinical efficacy of the drug was evaluated in 445 patients with various infections. Cefditoren pivoxil was administered at daily doses of 9-18 mg/kg divided into 3 equal doses to most patients. Daily doses of > 7.5-10.5 mg/kg were given to 48.8% of the patients. The overall clinical efficacy rate was 97.3%, and this drug was effective in 97.5% of the 319 patients for whom the causative pathogens were identified and in 96.8% of the 126 patients with infections for whom the causative pathogens were unknown. The efficacy rate at daily doses of > 7.5-10.5 mg/kg was 97.2%, similar to that obtained at daily doses of > 10.5-19.5 mg/kg (97.0%). The bacteriological eradication rate was 90.4%. The efficacy and eradication rates for 66 patients who had not responded to previous chemotherapy were 95.5% (63/66) and 89.4%, respectively. Side effects occurred in 19 (4.2%) of 456 patients subjected to safety analyses. The primary side effect was diarrhea but no serious side effects were noted. As abnormal laboratory test results, moderate increases of the eosinophils and platelets counts as well as moderate elevations of the transaminases were observed. These abnormalities are also seen with other cephems and to a similar extent. No particular and serious problems were associated with administration of this drug. Based on the above results, cefditoren pivoxil is considered to be very useful at a dose level of 3 mg/kg t.i.d. against most infections encountered in the pediatric field.

摘要

头孢妥仑匹酯颗粒(ME1207)是一种新型口服头孢菌素,对其进行了儿科领域的药代动力学和临床评估,获得以下结果:1. 药代动力学 给婴儿单次口服3mg(效价)/kg和6mg/kg剂量后,Cmax分别为1.54±0.68和2.85±1.03μg/ml;Tmax分别为2.27±1.08和2.06±1.16小时;T 1/2分别为2.22±1.95和1.68±0.66小时;AUC(0-∞)分别为7.43±3.68和11.90±4.51μg·hr/ml。这些数值表明该药物具有剂量依赖性药代动力学行为。给药后2-4小时尿浓度达到峰值。前8小时的尿回收率在3mg/kg时为19.4±6.6%,在6mg/kg时为17.1±5.2%。2. 临床结果 对445例各种感染患者评估了该药物的临床疗效。大多数患者给予头孢妥仑匹酯每日剂量9-18mg/kg,分3等份给药。48.8%的患者每日剂量>7.5-10.5mg/kg。总体临床有效率为97.3%,该药物对319例已确定病原体的患者有效率为97.5%,对126例病原体不明的感染患者有效率为96.8%。每日剂量>7.5-10.5mg/kg时的有效率为97.2%,与每日剂量>10.5-19.5mg/kg时的有效率(97.0%)相似。细菌清除率为90.4%。对先前化疗无反应的66例患者的有效率和清除率分别为95.5%(63/66)和89.4%。456例接受安全性分析的患者中有19例(4.2%)出现副作用。主要副作用为腹泻,但未观察到严重副作用。作为异常实验室检查结果,观察到嗜酸性粒细胞和血小板计数适度增加以及转氨酶适度升高。这些异常在其他头孢菌素中也有出现,且程度相似。该药物给药未出现特殊严重问题。基于上述结果,头孢妥仑匹酯被认为以3mg/kg每日3次的剂量水平对儿科领域遇到的大多数感染非常有用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验